Vapotherm, Inc. (VAPO) News
Filter VAPO News Items
VAPO News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
VAPO News Highlights
- VAPO's 30 day story count now stands at 4.
- Over the past 17 days, the trend for VAPO's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
Latest VAPO News From Around the Web
Below are the latest news stories about VAPOTHERM INC that investors may wish to consider to help them evaluate VAPO as an investment opportunity.
OTC Markets Group Welcomes Vapotherm, Inc. to OTCQXNEW YORK, Dec. 15, 2023 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for 12,000 U.S. and international securities, today announced Vapotherm, Inc. (OTCQX: VAPO), a global medical technology company specializing in the development and commercialization of its proprietary Vapotherm high-velocity therapy® products for patients of all ages experiencing respiratory distress, has qualified to trade on the OTCQX® Best Market. Vapotherm, Inc. voluntarily transf |
Vapotherm Announces Suspension of NYSE Listing Common Stock Expected to Begin Trading Promptly on OTCQXVapotherm, Inc. (NYSE: VAPO), ("Vapotherm" or the "Company") today announced it has received notice that the New York Stock Exchange ("NYSE") has determined to suspend trading of – and commence proceedings to delist – shares of the Company's common stock, effective immediately. This suspension was made because the Company fell below the NYSE's continued listing standard requiring listed companies to maintain an average global market capitalization over a consecutive 30 trading day period of at l |
Vapotherm Announces Notification to New York Stock Exchange of Intention to Voluntarily Delist Common Stock Application Pending to Transfer Shares to OTCQXVapotherm, Inc. (NYSE: VAPO), ("Vapotherm" or the "Company") today announced its intention to voluntarily delist its common stock from The New York Stock Exchange ("NYSE") and its filing of an application to have its common stock quoted on the OTCQX Marketplace ("OTCQX"). |
Vapotherm Educates over 8,000 Clinicians in Respiratory Care MonthVapotherm, Inc. (NYSE: VAPO), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which are used to treat patients of all ages suffering from respiratory distress is excited to announce the participation of over 8,000 clinicians in interactive, digital based, evidence based education focused on a variety of respiratory clinical topics. The education was free to clincians in celebration of Respiratory C |
Vapotherm, Inc. (NYSE:VAPO) Q3 2023 Earnings Call TranscriptVapotherm, Inc. (NYSE:VAPO) Q3 2023 Earnings Call Transcript November 8, 2023 Vapotherm, Inc. misses on earnings expectations. Reported EPS is $-2.38 EPS, expectations were $-2.2. Operator: Good afternoon, and welcome to Vapotherm’s Third Quarter 2023 Financial Results Conference Call. [Operator Instructions] It is now my pleasure to turn today’s conference over to Dorota Mckay, Vapotherm’s […] |
Vapotherm Reports Third Quarter 2023 Financial ResultsVapotherm, Inc. (NYSE: VAPO), ("Vapotherm" or the "Company"), today announced third quarter 2023 financial results and related highlights. |
3 Stocks Set to Rocket When the Bears Get Short-SqueezedSome investments could skyrocket when the bears get short-squeezed. |
Vapotherm To Report Third Quarter 2023 Financial ResultsVapotherm, Inc. (NYSE: VAPO), ("Vapotherm" or the "Company"), today announced that it will release financial results for the third quarter of 2023 after the close of trading on Wednesday, November 8, 2023. Vapotherm's management team will host a conference call beginning at 4:30 p.m. ET to discuss the financial results and recent business developments. |
Computational Fluid Dynamics (CFD) modeling further distinguishes Vapotherm High Velocity Therapy from generic high flow cannulasEXETER, N.H., October 04, 2023--Vapotherm, Inc. (NYSE: VAPO), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which are used to treat patients of all ages suffering from respiratory distress, today announced the online publication of "Validation of Human Upper Computational Fluid Dynamics Model for Turbulent Mixing" in the Journal of Fluid Dynamics. The full article will be published in the Decembe |
Pilot Study demonstrates Vapotherm HVNI technology is more effective than standard oxygen therapy for treatment of acute asthma in childrenEXETER, N.H., September 25, 2023--Vapotherm, Inc. (NYSE: VAPO), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which are used to treat patients of all ages suffering from respiratory distress, today announced the presentation of an Investigator-initiated clinical trial, "High flow humidified oxygen as an early intervention in children with acute severe asthma - a feasibility randomized controlled |